Dosage guide · 10 mg vial

FOXO4-DRI Dosage Protocol

D-retro-inverso senolytic peptide · FOXO4–p53 interaction blocker

The attributed educational schedule uses 250 mcg once daily in weeks 1–4, 375 mcg in weeks 5–8, then 500 mcg in weeks 9–16. With 3 mL of bacteriostatic water, a 10 mg vial is 3.33 mg/mL, so the 250 mcg start amount is 7.5 units (0.075 mL) on a U-100 syringe.

How oftenOnce daily

Starting dose250 mcg

Start = units7.5 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

FOXO4-DRI 10 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About FOXO4-DRI References

01 · DOSAGE CHART

FOXO4-DRI dosage chart

16-week daily reference schedule · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the mix used by the attributed 10 mg reference protocol, giving 3.33 mg/mL.

FOXO4-DRI dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Weeks 1–4Start	250 mcg	7.5 units0.075 mL
Weeks 5–8	375 mcg	11.2 units0.112 mL
Weeks 9–12Max	500 mcg	15 units0.15 mL
Weeks 13–16	500 mcg	15 units0.15 mL

Once daily · any consistent time · subcutaneous injection

The attributed source holds each amount for 4 weeks and ends after week 16.

This is an educational reference schedule, not a clinically established human dose.

Community-reference amounts — FOXO4-DRI has no approved or clinically established human dose. Education only, not medical advice. Dose amounts adapted from FOXO4-DRI 10 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

2FOXO4-DRI 10 mg vials17.5 mg needed in total

581 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle6 mL used for mixing

116Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.075 mL

Equivalent U-100 volume scale position

7.5markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About FOXO4-DRI

Protocol overview

Starting dose: 250 mcg once daily for weeks 1–4
How it increases: 375 mcg for weeks 5–8, then 500 mcg for weeks 9–16
Frequency: Once daily
When to take it: Any consistent time of day
Source schedule length: 16 weeks
Common mix: 3 mL bacteriostatic water → 3.33 mg/mL

Storage

Before mixing: No verified manufacturer storage directions are available for this unstocked 10 mg reference vial; follow its label.
After mixing: Refrigerate at 2–8 °C; this generic handling advice does not set a validated beyond-use date.
Never: Use a mixed vial that is cloudy or contains visible particles.

How it works

FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt binding between FOXO4 and p53. In cellular experiments, this released active p53 from the nucleus and activated caspase-dependent apoptosis in senescent cells.

The original research and later keloid work tested this idea in cells, organ cultures and mice. These preclinical findings do not show that selectively clearing senescent cells is effective or safe in people.

Illustrated mechanism explainer

What the research shows

In the original 2017 mouse chemotoxicity model, FOXO4-DRI was given intravenously at 5 mg/kg on days 1, 3 and 5 after doxorubicin; the findings were in mice, not people.
A 2020 study in naturally aged 20–24-month-old male mice used 5 mg/kg intraperitoneally every other day for 3 administrations. Serum testosterone was significantly higher 30 days later; the reported group size was 6.
A 2024 aged-mouse paper reported increased sperm quality and improved spermatogenesis after FOXO4-DRI treatment, while a 2025 paper reported apoptosis in keloid fibroblast and organ-culture models. Neither is human dosing or efficacy evidence.
The ClinicalTrials.gov FOXO4-DRI search opened for this guide returned no studies. The 250–500 mcg chart amounts therefore do not come from a human clinical dose-escalation.
An ARTG search for FOXO4-DRI returned no matching entry, and the DailyMed SPL API returned zero labels. FOXO4-DRI should not be presented as a TGA- or FDA-approved medicine.

Reported side effects

The opened primary sources provide no human adverse-event rates, so human safety, interactions and contraindications are unknown.
The cited experiments are in cells, organ cultures and mice; their results cannot establish the tolerability of 250–500 mcg given subcutaneously in people.
FOXO4-DRI is intended to trigger apoptosis in experimental senescent cells, but possible off-target effects in humans have not been characterised.

Important notes

FOXO4-DRI is not an approved medicine in Australia: the ARTG search opened for this guide returned no matching record.
Competitive athletes should treat it as prohibited at all times: WADA S0 prohibits pharmacological substances with no current governmental approval for human therapeutic use.
There is no clinically established human dose, efficacy or safety profile; do not use preclinical senolytic findings as evidence of treatment benefit.
The reference chart is not comparable with the 5 mg/kg intravenous or intraperitoneal animal regimens in the published studies.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

FOXO4-DRI questions

How many units is 250 mcg of FOXO4-DRI?

With 3 mL in a 10 mg vial (3.33 mg/mL), 250 mcg is 7.5 units, or 0.075 mL, on a U-100 syringe.

How much bacteriostatic water is used for a 10 mg FOXO4-DRI vial?

The attributed 10 mg reference protocol uses 3 mL, making 3.33 mg/mL. At that concentration, 375 mcg is 11.25 units (0.1125 mL) and 500 mcg is 15 units (0.15 mL) on a U-100 syringe.

How long does a 10 mg FOXO4-DRI vial last?

Ignoring preparation losses, 10 mg provides 40 once-daily 250 mcg amounts, 26.67 once-daily 375 mcg amounts, or 20 once-daily 500 mcg amounts.

07 · SOURCES